董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Denise Scots Knight | 女 | Chief Executive Officer and Director | 67 | 273.25万美元 | 2314.04 | 2026-05-14 |
| Anders Ekblom | 男 | Independent Director | 71 | 19.80万美元 | 156.22 | 2026-05-14 |
| Jeremy Bender | 男 | Independent Director | 54 | 19.08万美元 | 143.53 | 2026-05-14 |
| Deepika R. Pakianathan | 女 | Independent Director | 61 | 未披露 | 未持股 | 2026-05-14 |
| Daniel Shames | 男 | Independent Director | 80 | 18.12万美元 | 87.58 | 2026-05-14 |
| Marc Yoskowitz | 男 | Independent Director | 51 | 18.12万美元 | 87.58 | 2026-05-14 |
| Pierre Jacquet | 男 | Independent Director | 59 | 18.60万美元 | 127.20 | 2026-05-14 |
| Jeremy Bender | 男 | Independent Director | 54 | 未披露 | 未持股 | 2026-05-14 |
| Justin Roberts | 男 | Independent Director | 43 | 未披露 | 未持股 | 2026-05-14 |
| Deepika R. Pakianathan | 女 | Independent Director | 61 | 20.38万美元 | 50.75 | 2026-05-14 |
| Michael S. Wyzga | 男 | Independent Director and Chairman of the Board | 71 | 23.42万美元 | 149.78 | 2026-05-14 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Denise Scots Knight | 女 | Chief Executive Officer and Director | 67 | 273.25万美元 | 2314.04 | 2026-05-14 |
| Charles Sermon | 男 | General Counsel and Business Development | 56 | 117.19万美元 | 710.70 | 2026-05-14 |
| Alexandra Hughes Wilson | 女 | Chief Patient Access and Commercial Planning | 54 | 13.28万美元 | 未持股 | 2026-05-14 |
| John Lewicki | 男 | Chief Scientific Officer | 74 | 未披露 | 未持股 | 2026-05-14 |
| Christine Fox | 女 | Chief Financial Officer | 45 | 113.27万美元 | 546.02 | 2026-05-14 |
董事简历
中英对照 | 中文 | 英文- Denise Scots Knight
-
Denise Scots Knight，是Mereo BioPharma Group plc（一家专业生物制药公司）的共同创始人，也是其首席执行官和董事会成员，她自2015年以来一直担任该职位。Scots-Knight博士在生物制药行业拥有超过25年的经验，从事研发管理工作，并担任风险投资家。从2010年到2015年，Scots-Knight博士是全球生命科学风险投资公司Phase4 Partners Ltd.的管理合伙人。2004年至2010年，Scots-Knight博士担任野村Phase4 Ventures的负责人，该公司是日本领先金融机构野村国际集团（Nomura International plc）的风险投资附属公司。Scots-Knight博士曾在Oncomed Pharmaceuticals, Inc.、β胞核嘧啶制药、Nabriva Therapeutics AG和AlbireO的董事会任职。此外，Scots-Knight博士还被Labiotech UG评为欧洲生物技术领域15位领先的女性之一。
Denise Scots Knight is a co founder of Mereo and has served as Mereo BioPharma Group plc Chief Executive Officer since July 2015 and as a member of Mereo BioPharma Group plc Board of Directors since Mereo BioPharma Group plc formation. Prior to co founding Mereo, she served as Managing Partner at Phase4 Partners Ltd. ("Phase4"), a venture capital firm investing globally in biotechnology companies which was an MBO from Nomura, where Dr Scots Knight previously worked. Dr. Scots Knight is currently a board member of Elanco Animal Health Incorporated and previously served as a member of the board of directors of Idenix Pharmaceuticals (acquired by Merck) and Albireo Pharma (acquired by Ipsen), and also previously served as a Trustee at the British Heart Foundation for nine years. Dr. Scots Knight holds a Ph.D. in biochemistry from the University of Birmingham and was a Fulbright Scholar at the University of Berkeley, California. - Denise Scots Knight，是Mereo BioPharma Group plc（一家专业生物制药公司）的共同创始人，也是其首席执行官和董事会成员，她自2015年以来一直担任该职位。Scots-Knight博士在生物制药行业拥有超过25年的经验，从事研发管理工作，并担任风险投资家。从2010年到2015年，Scots-Knight博士是全球生命科学风险投资公司Phase4 Partners Ltd.的管理合伙人。2004年至2010年，Scots-Knight博士担任野村Phase4 Ventures的负责人，该公司是日本领先金融机构野村国际集团（Nomura International plc）的风险投资附属公司。Scots-Knight博士曾在Oncomed Pharmaceuticals, Inc.、β胞核嘧啶制药、Nabriva Therapeutics AG和AlbireO的董事会任职。此外，Scots-Knight博士还被Labiotech UG评为欧洲生物技术领域15位领先的女性之一。
- Denise Scots Knight is a co founder of Mereo and has served as Mereo BioPharma Group plc Chief Executive Officer since July 2015 and as a member of Mereo BioPharma Group plc Board of Directors since Mereo BioPharma Group plc formation. Prior to co founding Mereo, she served as Managing Partner at Phase4 Partners Ltd. ("Phase4"), a venture capital firm investing globally in biotechnology companies which was an MBO from Nomura, where Dr Scots Knight previously worked. Dr. Scots Knight is currently a board member of Elanco Animal Health Incorporated and previously served as a member of the board of directors of Idenix Pharmaceuticals (acquired by Merck) and Albireo Pharma (acquired by Ipsen), and also previously served as a Trustee at the British Heart Foundation for nine years. Dr. Scots Knight holds a Ph.D. in biochemistry from the University of Birmingham and was a Fulbright Scholar at the University of Berkeley, California.
- Anders Ekblom
-
Anders Ekblom自2015年7月起担任Mereo董事会成员。Ekblom博士曾在阿斯利康公司担任多个执行职位，包括执行Vice President全球药物开发、执行Vice President全球药物开发、全球临床开发主管、全球治疗领域主管、全球科学和技术集成主管，以及阿斯利康公司瑞典分公司的首席执行官。他目前担任ELYPTA AB和TFS International AB的董事会主席，以及Alligator Bioscience AB、Anamar AB、婴儿细菌疗法AB和利欧股份Pharma A/S的董事会成员。Ekblom博士是董事会认证的医生，也是卡罗林斯卡学院的副教授。Ekblom博士拥有卡罗林斯卡学院（Karolinska Institutet）的D.D.S.，M.D.和博士学位。
Anders Ekblom has extensive experience as an executive and leader with broad business knowledge from senior roles in the biopharmaceutical industry, with global experience delivering products, projects, productivity and change management. He is currently Chairman of Xspray Pharma AB and Chairman/Non Executive Board member of several other biotech companies,. During two decades at AstraZeneca, he was a member of global executive teams including Executive VP Global Medicines Development, Global Head Clinical Development, Global Therapy Area Head, Global Head Science and Technology Integration, and CEO AstraZeneca AB Sweden. Dr. Ekblom is also a board certified MD (Anaesthesiology and Intensive Care), PhD, DDS, an Associate Professor at Karolinska Institute, Stockholm, Sweden, and a fellow of the Royal Swedish Academy of Engineering Sciences. - Anders Ekblom自2015年7月起担任Mereo董事会成员。Ekblom博士曾在阿斯利康公司担任多个执行职位，包括执行Vice President全球药物开发、执行Vice President全球药物开发、全球临床开发主管、全球治疗领域主管、全球科学和技术集成主管，以及阿斯利康公司瑞典分公司的首席执行官。他目前担任ELYPTA AB和TFS International AB的董事会主席，以及Alligator Bioscience AB、Anamar AB、婴儿细菌疗法AB和利欧股份Pharma A/S的董事会成员。Ekblom博士是董事会认证的医生，也是卡罗林斯卡学院的副教授。Ekblom博士拥有卡罗林斯卡学院（Karolinska Institutet）的D.D.S.，M.D.和博士学位。
- Anders Ekblom has extensive experience as an executive and leader with broad business knowledge from senior roles in the biopharmaceutical industry, with global experience delivering products, projects, productivity and change management. He is currently Chairman of Xspray Pharma AB and Chairman/Non Executive Board member of several other biotech companies,. During two decades at AstraZeneca, he was a member of global executive teams including Executive VP Global Medicines Development, Global Head Clinical Development, Global Therapy Area Head, Global Head Science and Technology Integration, and CEO AstraZeneca AB Sweden. Dr. Ekblom is also a board certified MD (Anaesthesiology and Intensive Care), PhD, DDS, an Associate Professor at Karolinska Institute, Stockholm, Sweden, and a fellow of the Royal Swedish Academy of Engineering Sciences.
- Jeremy Bender
-
Jeremy Bender自2020年9月起担任我们的首席执行官，总裁兼董事会成员。在加入Day One之前，Bender博士于2018年3月至2020年9月担任制药公司Gilead Sciences的公司发展副总裁。在此之前，他于2015年7月至2018年3月担任Tizona Therapeutics的首席运营官，并于2012年10月至2015年7月担任专门从事癌症和自身免疫疗法的生物技术公司Sutro Biopharma的首席商务官。加入Sutro Biopharma公司之前，他曾担任Allos Therapeutics公司（生物技术公司，专注于癌症治疗）的公司发展副总裁（从2006年1月到2012年9月）。Bender博士的职业生涯始于波士顿咨询集团（Boston Consulting Group），这是一家管理咨询公司。Bender博士还是Mereo Biopharma董事会的独立董事。Bender博士拥有斯坦福大学生物科学学士学位，科罗拉多大学微生物学和免疫学博士学位以及麻省理工学院斯隆管理学院的工商管理硕士学位。
Jeremy Bender has served as Chief Executive Officer, President and a member of board of directors since September 2020. Prior to joining Day One, Dr. Bender was Vice President of Corporate Development at Gilead Sciences, Inc., a pharmaceutical company, from March 2018 to September 2020. Prior to that, he was Chief Operating Officer of Tizona Therapeutics, Inc. from July 2015 to March 2018 and Chief Business Officer of Sutro Biopharma, a biotechnology company specializing in cancer and autoimmune therapeutics, from October 2012 to July 2015. Prior to joining Sutro Biopharma, Inc., he was Vice President of Corporate Development at Allos Therapeutics Inc., a biotechnology company focused on cancer treatments, from January 2006 to September 2012. Dr. Bender began his career in the life sciences practice at Boston Consulting Group, a management consulting company. Dr. Bender also sits on the board of Mereo BioPharma Group plc, a biotechnology company, since October 2020 as an independent board member. From October 2023 to June 2024, Dr. Bender also served as a director of Fusion Pharmaceuticals, Inc., a biopharmaceutical company. Dr. Bender holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an M.B.A. from the MIT Sloan School of Management. - Jeremy Bender自2020年9月起担任我们的首席执行官，总裁兼董事会成员。在加入Day One之前，Bender博士于2018年3月至2020年9月担任制药公司Gilead Sciences的公司发展副总裁。在此之前，他于2015年7月至2018年3月担任Tizona Therapeutics的首席运营官，并于2012年10月至2015年7月担任专门从事癌症和自身免疫疗法的生物技术公司Sutro Biopharma的首席商务官。加入Sutro Biopharma公司之前，他曾担任Allos Therapeutics公司（生物技术公司，专注于癌症治疗）的公司发展副总裁（从2006年1月到2012年9月）。Bender博士的职业生涯始于波士顿咨询集团（Boston Consulting Group），这是一家管理咨询公司。Bender博士还是Mereo Biopharma董事会的独立董事。Bender博士拥有斯坦福大学生物科学学士学位，科罗拉多大学微生物学和免疫学博士学位以及麻省理工学院斯隆管理学院的工商管理硕士学位。
- Jeremy Bender has served as Chief Executive Officer, President and a member of board of directors since September 2020. Prior to joining Day One, Dr. Bender was Vice President of Corporate Development at Gilead Sciences, Inc., a pharmaceutical company, from March 2018 to September 2020. Prior to that, he was Chief Operating Officer of Tizona Therapeutics, Inc. from July 2015 to March 2018 and Chief Business Officer of Sutro Biopharma, a biotechnology company specializing in cancer and autoimmune therapeutics, from October 2012 to July 2015. Prior to joining Sutro Biopharma, Inc., he was Vice President of Corporate Development at Allos Therapeutics Inc., a biotechnology company focused on cancer treatments, from January 2006 to September 2012. Dr. Bender began his career in the life sciences practice at Boston Consulting Group, a management consulting company. Dr. Bender also sits on the board of Mereo BioPharma Group plc, a biotechnology company, since October 2020 as an independent board member. From October 2023 to June 2024, Dr. Bender also served as a director of Fusion Pharmaceuticals, Inc., a biopharmaceutical company. Dr. Bender holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an M.B.A. from the MIT Sloan School of Management.
- Deepika R. Pakianathan
-
Deepika R. Pakianathan，博士，自2020年7月起担任Theravance Biopharma, Inc.的董事。2001年以来，她一直担任Delphi Ventures（风险投资公司）的管理成员。她也是Redd Pharmaceuticals, Inc.（一家私营制药公司）的首席执行官（2019年9月以来）。从2007年到2019年，她担任Alder Pharmaceuticals, Inc.的董事会成员。从2004年到2016年，她担任Alexza Pharmaceuticals, Inc.的董事会成员。从1998年到2001年，Pakianathan博士担任JP Morgan Chase & Company的医疗保健集团副总裁。从1993年到1997年，她担任Genentech Corporation免疫学系的博士后科学家。她目前担任Calithera Biosciences, Inc.、Karyopharm Therapeutics, Inc.、Mereo Biopharma Group PLC和FS Development Corp. II （SPAC）的董事会成员。她持有维克森林大学（Wake Forest University）的硕士学位和博士学位，印度孟买大学（the University of Bombay）的学士学位，以及印度孟买大学（the University of Bombay）癌症研究所（the Cancer Research Institute）的硕士学位。
Deepika R. Pakianathan is a Managing Member at Delphi Ventures and leads all of the firm's biotechnology investment activities. She joined the Mereo Board subsequent to the merger with OncoMed Pharmaceuticals. She currently serves on the boards of Theravance Biopharma, Inc. and Karyopharm Therapeutics, Inc. and previously served on a number of boards, including Calithera Biosciences. Dr. Pakianathan joined Delphi in 2001 to build and lead the firm's biotechnology investment practice. Prior to joining Delphi, Deepa was a Vice President in the healthcare group at J.P. Morgan. Prior to that, she was a biotechnology research analyst at Genesis Merchant Group. She worked as a postdoctoral scientist in the Immunology Department at Genentech Corporation from 1993 to 1997. Deepa received her Ph.D. and MS from Wake Forest University and her MSc and BSc from the University of Bombay. - Deepika R. Pakianathan，博士，自2020年7月起担任Theravance Biopharma, Inc.的董事。2001年以来，她一直担任Delphi Ventures（风险投资公司）的管理成员。她也是Redd Pharmaceuticals, Inc.（一家私营制药公司）的首席执行官（2019年9月以来）。从2007年到2019年，她担任Alder Pharmaceuticals, Inc.的董事会成员。从2004年到2016年，她担任Alexza Pharmaceuticals, Inc.的董事会成员。从1998年到2001年，Pakianathan博士担任JP Morgan Chase & Company的医疗保健集团副总裁。从1993年到1997年，她担任Genentech Corporation免疫学系的博士后科学家。她目前担任Calithera Biosciences, Inc.、Karyopharm Therapeutics, Inc.、Mereo Biopharma Group PLC和FS Development Corp. II （SPAC）的董事会成员。她持有维克森林大学（Wake Forest University）的硕士学位和博士学位，印度孟买大学（the University of Bombay）的学士学位，以及印度孟买大学（the University of Bombay）癌症研究所（the Cancer Research Institute）的硕士学位。
- Deepika R. Pakianathan is a Managing Member at Delphi Ventures and leads all of the firm's biotechnology investment activities. She joined the Mereo Board subsequent to the merger with OncoMed Pharmaceuticals. She currently serves on the boards of Theravance Biopharma, Inc. and Karyopharm Therapeutics, Inc. and previously served on a number of boards, including Calithera Biosciences. Dr. Pakianathan joined Delphi in 2001 to build and lead the firm's biotechnology investment practice. Prior to joining Delphi, Deepa was a Vice President in the healthcare group at J.P. Morgan. Prior to that, she was a biotechnology research analyst at Genesis Merchant Group. She worked as a postdoctoral scientist in the Immunology Department at Genentech Corporation from 1993 to 1997. Deepa received her Ph.D. and MS from Wake Forest University and her MSc and BSc from the University of Bombay.
- Daniel Shames
-
Daniel Shames自2022年11月起担任Mereo BioPharma Group PLC董事会成员。Shames博士曾担任Daniel A. Shames Consulting总裁，为100多家生物技术和制药客户提供监管服务。在开始咨询之前，Shames博士在FDA工作了12年，期间他参与了数百种药物的安全性和有效性审查。最近，Shames博士在2006年至2008年期间担任药物评价III办公室副主任，同时还担任胃肠病学和先天错误产品司司长。在此之前，他曾于2001年至2006年担任生殖和泌尿外科药物总监。在加入FDA之前，Shames博士创立了Carolina Urocorp，经营一家私人医疗诊所，并在美国陆军医疗队担任少校。Shames博士在布兰代斯大学获得本科学位，在乔治城大学医学院获得医学博士学位，并在宾夕法尼亚大学做泌尿外科住院医师。
Daniel Shames has served on Mereo BioPharma Group plc Board of Directors since November 2022. Dr. Shames has served as President of Daniel A. Shames Consulting, providing regulatory services to over 100 biotechnology and pharmaceutical clients. Prior to starting his consultancy, Dr. Shames spent 12 years at the FDA during which time he was involved in the safety and efficacy review of hundreds of drugs. Most recently Dr. Shames served as Deputy Director, Office of Drug Evaluation III from 2006 to 2008, while also serving as Director of the Division of Gastroenterology and Inborn Error Products. Prior to that he was Director of Reproductive and Urologic Drugs from 2001 to 2006. Before joining the FDA, Dr. Shames founded Carolina Urocorp, operated a private medical practice, and was as Major in the U.S. Army Medical Corps. Dr. Shames received his undergraduate degree from Brandeis University, his M.D. from Georgetown University School of Medicine, and did his urology residency at the University of Pennsylvania. - Daniel Shames自2022年11月起担任Mereo BioPharma Group PLC董事会成员。Shames博士曾担任Daniel A. Shames Consulting总裁，为100多家生物技术和制药客户提供监管服务。在开始咨询之前，Shames博士在FDA工作了12年，期间他参与了数百种药物的安全性和有效性审查。最近，Shames博士在2006年至2008年期间担任药物评价III办公室副主任，同时还担任胃肠病学和先天错误产品司司长。在此之前，他曾于2001年至2006年担任生殖和泌尿外科药物总监。在加入FDA之前，Shames博士创立了Carolina Urocorp，经营一家私人医疗诊所，并在美国陆军医疗队担任少校。Shames博士在布兰代斯大学获得本科学位，在乔治城大学医学院获得医学博士学位，并在宾夕法尼亚大学做泌尿外科住院医师。
- Daniel Shames has served on Mereo BioPharma Group plc Board of Directors since November 2022. Dr. Shames has served as President of Daniel A. Shames Consulting, providing regulatory services to over 100 biotechnology and pharmaceutical clients. Prior to starting his consultancy, Dr. Shames spent 12 years at the FDA during which time he was involved in the safety and efficacy review of hundreds of drugs. Most recently Dr. Shames served as Deputy Director, Office of Drug Evaluation III from 2006 to 2008, while also serving as Director of the Division of Gastroenterology and Inborn Error Products. Prior to that he was Director of Reproductive and Urologic Drugs from 2001 to 2006. Before joining the FDA, Dr. Shames founded Carolina Urocorp, operated a private medical practice, and was as Major in the U.S. Army Medical Corps. Dr. Shames received his undergraduate degree from Brandeis University, his M.D. from Georgetown University School of Medicine, and did his urology residency at the University of Pennsylvania.
- Marc Yoskowitz
-
Marc Yoskowitz自2022年11月起担任Mereo BioPharma Group PLC董事会成员。Yoskowitz先生是Evozyne，Inc.的首席执行官和Keenova Therapeutics plc的主席。在此之前，他曾担任Tempus，Inc.生命科学部门执行副总裁兼首席战略官。Yoskowitz先生还曾担任辉瑞 Essential Health首席商务官，领导辉瑞投资组合内的一系列企业计划，担任Hospira战略和企业发展高级副总裁，并且是执行委员会成员。职业生涯早期，Yoskowitz先生在一家专业制药公司领导业务发展，在麦肯锡公司工作了八年，担任副校长，并在纽约Davis，Polk & Wardwell开始了他的并购律师生涯。Yoskowitz先生以优异成绩获得了圣路易斯华盛顿大学的学士学位，并拥有哥伦比亚大学法学院的法学博士学位。
Marc Yoskowitz has served on Mereo BioPharma Group plc Board of Directors since November 2022. Mr. Yoskowitz is Chief Executive Officer of Evozyne, Inc. and Chair of Keenova Therapeutics plc. Previously, he served as EVP and Chief Strategy Officer, Life Sciences at Tempus, Inc. Mr. Yoskowitz has also served as Chief Business Officer, Pfizer Essential Health, leading a range of corporate initiatives within the Pfizer portfolio, as SVP, Strategy and Corporate Development at Hospira, and was a member of the Executive Committee. Earlier in his career, Mr. Yoskowitz led business development at a specialty pharmaceutical company, spent eight years at McKinsey & Company where he was an Associate Principal, and began his career as an M&A lawyer at Davis, Polk & Wardwell in New York. Mr. Yoskowitz received a bachelor's degree magna cum laude from Washington University in St. Louis and holds a J.D. from Columbia University School of Law. - Marc Yoskowitz自2022年11月起担任Mereo BioPharma Group PLC董事会成员。Yoskowitz先生是Evozyne，Inc.的首席执行官和Keenova Therapeutics plc的主席。在此之前，他曾担任Tempus，Inc.生命科学部门执行副总裁兼首席战略官。Yoskowitz先生还曾担任辉瑞 Essential Health首席商务官，领导辉瑞投资组合内的一系列企业计划，担任Hospira战略和企业发展高级副总裁，并且是执行委员会成员。职业生涯早期，Yoskowitz先生在一家专业制药公司领导业务发展，在麦肯锡公司工作了八年，担任副校长，并在纽约Davis，Polk & Wardwell开始了他的并购律师生涯。Yoskowitz先生以优异成绩获得了圣路易斯华盛顿大学的学士学位，并拥有哥伦比亚大学法学院的法学博士学位。
- Marc Yoskowitz has served on Mereo BioPharma Group plc Board of Directors since November 2022. Mr. Yoskowitz is Chief Executive Officer of Evozyne, Inc. and Chair of Keenova Therapeutics plc. Previously, he served as EVP and Chief Strategy Officer, Life Sciences at Tempus, Inc. Mr. Yoskowitz has also served as Chief Business Officer, Pfizer Essential Health, leading a range of corporate initiatives within the Pfizer portfolio, as SVP, Strategy and Corporate Development at Hospira, and was a member of the Executive Committee. Earlier in his career, Mr. Yoskowitz led business development at a specialty pharmaceutical company, spent eight years at McKinsey & Company where he was an Associate Principal, and began his career as an M&A lawyer at Davis, Polk & Wardwell in New York. Mr. Yoskowitz received a bachelor's degree magna cum laude from Washington University in St. Louis and holds a J.D. from Columbia University School of Law.
- Pierre Jacquet
-
Pierre Jacquet目前是L.E.K. Consulting全球医疗保健业务的董事总经理兼副主席。他曾在L.E.K.担任过20多年的各种领导职务，包括全球主管、医疗保健实践、全球领导团队、美洲管理委员会以及各种合作伙伴运营委员会。在2001年加入L.E.K.之前，Jacquet博士在比利时列日大学接受外科住院医师培训，并在华盛顿癌症研究所担任研究员，在那里他撰写了40多篇出版物和演讲。除了在Mereo的董事会任职外，Jacquet博士还是Neurvati的董事、Life Science Cares的顾问委员会成员，此前还曾担任Osprey Pharmaceuticals的董事。他获得了弗吉尼亚大学达顿研究生院的工商管理硕士学位，以优异成绩毕业于比利时列日大学的医学专业，并获得了比利时列日大学生物医学科学的Summa Cum Laude哲学博士学位。
Pierre Jacquet is currently Managing Director and Vice Chairman of L.E.K. Consulting's Global Healthcare practice. He has served in a variety of leadership roles over 20 years at L.E.K., including Global Head, Healthcare Practice, Global Leadership Team, the Americas management committee, and various partner operating committees. Prior to joining L.E.K. in 2001, Dr. Jacquet was trained as a surgical resident at University of Liège, Belgium and served as a Fellow at the Washington Cancer Institute, where he authored over 40 publications and presentations. In addition to serving on Mereo's Board of Directors, Dr. Jacquet is a Director of Neurvati, on the Advisory Board of Life Science Cares, and previously served as a Director of Osprey Pharmaceuticals. He earned a M.B.A from the Darden Graduate School at the University of Virginia, graduated Magna Cum Laude in Medicine from the University of Liège in Belgium and was awarded a Summa Cum Laude Doctor of Philosophy in biomedical sciences from the University of Liège in Belgium. - Pierre Jacquet目前是L.E.K. Consulting全球医疗保健业务的董事总经理兼副主席。他曾在L.E.K.担任过20多年的各种领导职务，包括全球主管、医疗保健实践、全球领导团队、美洲管理委员会以及各种合作伙伴运营委员会。在2001年加入L.E.K.之前，Jacquet博士在比利时列日大学接受外科住院医师培训，并在华盛顿癌症研究所担任研究员，在那里他撰写了40多篇出版物和演讲。除了在Mereo的董事会任职外，Jacquet博士还是Neurvati的董事、Life Science Cares的顾问委员会成员，此前还曾担任Osprey Pharmaceuticals的董事。他获得了弗吉尼亚大学达顿研究生院的工商管理硕士学位，以优异成绩毕业于比利时列日大学的医学专业，并获得了比利时列日大学生物医学科学的Summa Cum Laude哲学博士学位。
- Pierre Jacquet is currently Managing Director and Vice Chairman of L.E.K. Consulting's Global Healthcare practice. He has served in a variety of leadership roles over 20 years at L.E.K., including Global Head, Healthcare Practice, Global Leadership Team, the Americas management committee, and various partner operating committees. Prior to joining L.E.K. in 2001, Dr. Jacquet was trained as a surgical resident at University of Liège, Belgium and served as a Fellow at the Washington Cancer Institute, where he authored over 40 publications and presentations. In addition to serving on Mereo's Board of Directors, Dr. Jacquet is a Director of Neurvati, on the Advisory Board of Life Science Cares, and previously served as a Director of Osprey Pharmaceuticals. He earned a M.B.A from the Darden Graduate School at the University of Virginia, graduated Magna Cum Laude in Medicine from the University of Liège in Belgium and was awarded a Summa Cum Laude Doctor of Philosophy in biomedical sciences from the University of Liège in Belgium.
- Jeremy Bender
-
Jeremy Bender现任DayOne Biopharmaceuticals首席执行官兼总裁。在加入DayOne之前，Bender博士于2018年3月至2020年9月在制药公司吉利德科学担任企业发展副总裁。在此之前，他于2015年7月至2018年3月担任Tizona Therapeutics的首席运营官，并于2012年10月至2015年7月担任专注于癌症和自身免疫疗法的生物技术公司Sutro Biopharma的首席商务官。在加入Sutro Biopharma之前，他于2006年1月至2012年9月在专注于癌症治疗的生物技术公司阿洛斯治疗担任企业发展副总裁。Bender博士的职业生涯始于管理咨询公司波士顿咨询集团的生命科学实践。Bender博士拥有斯坦福大学生物科学学士学位、科罗拉多大学微生物学和免疫学博士学位以及麻省理工学院斯隆管理学院工商管理硕士学位。
Jeremy Bender is currently the Chief Executive Officer and President of DayOne Biopharmaceuticals. Prior to joining DayOne, Dr. Bender was Vice President of Corporate Development at Gilead Sciences, a pharmaceutical company, from March 2018 to September 2020. Prior to that, he was Chief Operating Officer of Tizona Therapeutics from July 2015 to March 2018 and Chief Business Officer of Sutro Biopharma, a biotechnology company specializing in cancer and autoimmune therapeutics, from October 2012 to July 2015. Prior to joining Sutro Biopharma, he was Vice President of Corporate Development at Allos Therapeutics, a biotechnology company focused on cancer treatments, from January 2006 to September 2012. Dr. Bender began his career in the life sciences practice at Boston Consulting Group, a management consulting company. Dr. Bender holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an M.B.A. from the MIT Sloan School of Management. - Jeremy Bender现任DayOne Biopharmaceuticals首席执行官兼总裁。在加入DayOne之前，Bender博士于2018年3月至2020年9月在制药公司吉利德科学担任企业发展副总裁。在此之前，他于2015年7月至2018年3月担任Tizona Therapeutics的首席运营官，并于2012年10月至2015年7月担任专注于癌症和自身免疫疗法的生物技术公司Sutro Biopharma的首席商务官。在加入Sutro Biopharma之前，他于2006年1月至2012年9月在专注于癌症治疗的生物技术公司阿洛斯治疗担任企业发展副总裁。Bender博士的职业生涯始于管理咨询公司波士顿咨询集团的生命科学实践。Bender博士拥有斯坦福大学生物科学学士学位、科罗拉多大学微生物学和免疫学博士学位以及麻省理工学院斯隆管理学院工商管理硕士学位。
- Jeremy Bender is currently the Chief Executive Officer and President of DayOne Biopharmaceuticals. Prior to joining DayOne, Dr. Bender was Vice President of Corporate Development at Gilead Sciences, a pharmaceutical company, from March 2018 to September 2020. Prior to that, he was Chief Operating Officer of Tizona Therapeutics from July 2015 to March 2018 and Chief Business Officer of Sutro Biopharma, a biotechnology company specializing in cancer and autoimmune therapeutics, from October 2012 to July 2015. Prior to joining Sutro Biopharma, he was Vice President of Corporate Development at Allos Therapeutics, a biotechnology company focused on cancer treatments, from January 2006 to September 2012. Dr. Bender began his career in the life sciences practice at Boston Consulting Group, a management consulting company. Dr. Bender holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an M.B.A. from the MIT Sloan School of Management.
- Justin Roberts
-
Justin Roberts自2022年11月起担任Mereo BioPharma Group PLC董事会成员。罗伯茨先生是Rubric Capital Management LP的合伙人，自2016年公司成立以来，他一直担任这一职务。在加入Rubric之前，他在Point72资产管理公司工作了七年。罗伯茨先生目前在TherapeuticSMD，Inc.的董事会任职，还曾在ZS Associates、Moore Capital Management任职，并在雷曼兄弟公司的并购业务中作为投资银行家开始了他的职业生涯。罗伯茨先生以优异的成绩毕业于约翰霍普金斯大学。
Justin Roberts has served on Mereo BioPharma Group plc Board of Directors since November 2022. Mr. Roberts is a Partner at Rubric Capital Management LP, a role he has held since the formation of the company in 2016. Before Rubric he spent seven years at Point72 Asset Management. Mr. Roberts currently serves on the board of directors of TherapeuticsMD, Inc. and has also held roles at ZS Associates, Moore Capital Management, and began his career at Lehman Brothers as an investment banker in their M&A practice. Mr. Roberts graduated with honors from Johns Hopkins University. - Justin Roberts自2022年11月起担任Mereo BioPharma Group PLC董事会成员。罗伯茨先生是Rubric Capital Management LP的合伙人，自2016年公司成立以来，他一直担任这一职务。在加入Rubric之前，他在Point72资产管理公司工作了七年。罗伯茨先生目前在TherapeuticSMD，Inc.的董事会任职，还曾在ZS Associates、Moore Capital Management任职，并在雷曼兄弟公司的并购业务中作为投资银行家开始了他的职业生涯。罗伯茨先生以优异的成绩毕业于约翰霍普金斯大学。
- Justin Roberts has served on Mereo BioPharma Group plc Board of Directors since November 2022. Mr. Roberts is a Partner at Rubric Capital Management LP, a role he has held since the formation of the company in 2016. Before Rubric he spent seven years at Point72 Asset Management. Mr. Roberts currently serves on the board of directors of TherapeuticsMD, Inc. and has also held roles at ZS Associates, Moore Capital Management, and began his career at Lehman Brothers as an investment banker in their M&A practice. Mr. Roberts graduated with honors from Johns Hopkins University.
- Deepika R. Pakianathan
-
Deepika R. Pakianathan，她担任董事会的董事（2008年12月以来）。自2001年以来，她担任特尔斐投资公司（Delphi Ventures）（一个专注于医疗器械和生物技术投资的风险资本公司）的管理成员并且领导公司的生物技术投资活动。加入特尔斐投资公司（Delphi Ventures）之前，她担任摩根大通公司（JP Morgan）的医疗部门的副总裁。自2004年以来，她在Alexza Pharmaceuticals, Inc.（一个上市的制药公司）的董事会任职。在那里，她担任其薪酬委员会和提名和治理委员会的成员。她此前在PTC Therapeutics, Inc.（一个上市的制药公司）和Relypsa, Inc.（一个上市的制药公司）的董事会任职。她获得印度Bombay大学的学士学位、Bombay大学癌症研究所的硕士学位和Wake Forest大学的硕士和博士学位。
Deepika R. Pakianathan has served as a member of Karyopharm Therapeutics Inc.'s Board since 2013. Since 2001, Dr. Pakianathan has been a Managing Member at Delphi Ventures, a venture capital firm focused on biotechnology and medical device investments, where she leads the firm's biotechnology investment activities. Dr. Pakianathan also serves as the Chief Executive Officer of two biotechnology companies operating in stealth mode, one company since 2019 and the other company since August 2023. From 1998 to 2001, Dr. Pakianathan was a senior biotechnology banker at JPMorgan, a global investment bank, from 1997 to 1998, she was a research analyst covering biotechnology at Genesis Merchant Group Securities and from 1993 to 1997 she was a post doctoral research scientist at Genentech. Dr. Pakianathan has served on the board of directors of Theravance Biopharma, Inc., a public biopharmaceutical company, since 2020, where she also serves as chair of the nominating and governance committee and a member of the audit committee and the development and commercialization committee, and Mereo Biopharma Group PLC, a public biopharmaceutical company, since 2019, where she also serves as chair of its audit committee and a member of the remuneration committee. In 2020, Dr. Pakianathan was appointed to the board of directors of Palleon Pharmaceuticals, Inc., a biotechnology company, where she serves as lead director and chair of the audit committee and the compensation committee. In January 2021, Dr. Pakianathan was appointed to the board of Freenome Holdings, Inc., a diagnostic company, where she serves as chair of the audit committee and a member of the compensation committee. From 2020 to February 2021, Dr. Pakianathan served on the board of directors of Foresite Development Corp I, and from February 2021 to December 2021, Dr. Pakianathan served on the board of directors of Foresite Development Corp II, both public special purpose acquisition companies. Dr. Pakianathan also served on the board of directors of Calithera Biosciences, Inc., a public biopharmaceutical company, from 2010 to December 2023; the board of directors of Alder Biopharmaceuticals, Inc., a public biopharmaceutical company, from 2007 until 2019, when it was acquired by Lundbeck A/S; the board of directors of OncoMed Pharmaceuticals, Inc., a public biopharmaceutical company, from 2008 until 2019, when it was acquired by Mereo Biopharma Group PLC; and the board of directors of Alexza Pharmaceuticals, Inc., a public biopharmaceutical company, from 2004 to 2016, when it was acquired by Ferrer. Dr. Pakianathan holds a M.S. and Ph.D. from Wake Forest University, a B.Sc. from the University of Bombay, India and a M.Sc. from The Cancer Research Institute at the University of Bombay, India. - Deepika R. Pakianathan，她担任董事会的董事（2008年12月以来）。自2001年以来，她担任特尔斐投资公司（Delphi Ventures）（一个专注于医疗器械和生物技术投资的风险资本公司）的管理成员并且领导公司的生物技术投资活动。加入特尔斐投资公司（Delphi Ventures）之前，她担任摩根大通公司（JP Morgan）的医疗部门的副总裁。自2004年以来，她在Alexza Pharmaceuticals, Inc.（一个上市的制药公司）的董事会任职。在那里，她担任其薪酬委员会和提名和治理委员会的成员。她此前在PTC Therapeutics, Inc.（一个上市的制药公司）和Relypsa, Inc.（一个上市的制药公司）的董事会任职。她获得印度Bombay大学的学士学位、Bombay大学癌症研究所的硕士学位和Wake Forest大学的硕士和博士学位。
- Deepika R. Pakianathan has served as a member of Karyopharm Therapeutics Inc.'s Board since 2013. Since 2001, Dr. Pakianathan has been a Managing Member at Delphi Ventures, a venture capital firm focused on biotechnology and medical device investments, where she leads the firm's biotechnology investment activities. Dr. Pakianathan also serves as the Chief Executive Officer of two biotechnology companies operating in stealth mode, one company since 2019 and the other company since August 2023. From 1998 to 2001, Dr. Pakianathan was a senior biotechnology banker at JPMorgan, a global investment bank, from 1997 to 1998, she was a research analyst covering biotechnology at Genesis Merchant Group Securities and from 1993 to 1997 she was a post doctoral research scientist at Genentech. Dr. Pakianathan has served on the board of directors of Theravance Biopharma, Inc., a public biopharmaceutical company, since 2020, where she also serves as chair of the nominating and governance committee and a member of the audit committee and the development and commercialization committee, and Mereo Biopharma Group PLC, a public biopharmaceutical company, since 2019, where she also serves as chair of its audit committee and a member of the remuneration committee. In 2020, Dr. Pakianathan was appointed to the board of directors of Palleon Pharmaceuticals, Inc., a biotechnology company, where she serves as lead director and chair of the audit committee and the compensation committee. In January 2021, Dr. Pakianathan was appointed to the board of Freenome Holdings, Inc., a diagnostic company, where she serves as chair of the audit committee and a member of the compensation committee. From 2020 to February 2021, Dr. Pakianathan served on the board of directors of Foresite Development Corp I, and from February 2021 to December 2021, Dr. Pakianathan served on the board of directors of Foresite Development Corp II, both public special purpose acquisition companies. Dr. Pakianathan also served on the board of directors of Calithera Biosciences, Inc., a public biopharmaceutical company, from 2010 to December 2023; the board of directors of Alder Biopharmaceuticals, Inc., a public biopharmaceutical company, from 2007 until 2019, when it was acquired by Lundbeck A/S; the board of directors of OncoMed Pharmaceuticals, Inc., a public biopharmaceutical company, from 2008 until 2019, when it was acquired by Mereo Biopharma Group PLC; and the board of directors of Alexza Pharmaceuticals, Inc., a public biopharmaceutical company, from 2004 to 2016, when it was acquired by Ferrer. Dr. Pakianathan holds a M.S. and Ph.D. from Wake Forest University, a B.Sc. from the University of Bombay, India and a M.Sc. from The Cancer Research Institute at the University of Bombay, India.
- Michael S. Wyzga
-
Michael S. Wyzga，自2019年3月合并完成后担任董事会成员。在合并之前，Wyzga先生自2018年7月起担任X4董事会主席。Wyzga先生目前是MSW Consulting Inc.的总裁。2011年12月至2013年11月，Wyzga先生在上市的生物制药公司Radius Health, Inc.担任总裁兼首席执行官和董事会成员。在此之前，Wyzga先生曾在全球生物技术上市公司健赞担任多个高级管理职位。Wyzga先生于1998年2月加入健赞，最近于2003年5月至2011年11月担任财务执行副总裁，并于1999年7月至2011年11月担任首席财务官。2014年2月至2018年12月，Wyzga先生担任上市生物制药公司Akebia Therapeutics, Inc.的董事会成员，同时也是薪酬委员会成员和审计委员会主席。自2015年2月起，Wyzga先生还担任医疗技术上市公司Exact Sciences Corporation的董事会成员。自2013年10月起至2019年4月Oncomed Pharmaceuticals, Inc.与Mereo BioPharma Group plc进行企业合并之前，Wyzga先生一直担任Oncomed Pharmaceuticals, Inc.的董事会成员，同时他还是审计委员会的成员。自2016年2月起，Wyzga先生还担任泛欧交易所上市生物制药公司GenSight Biologics S.A.的董事会主席。Wyzga先生此前还曾担任β胞核嘧啶制药的董事会成员，并于2014年6月起担任上市生物制药公司Prosensa Holding B.V。的监事会成员，直至2014年12月BioMarin Falcon B.V。收购Prosensa.他获得了普罗维登斯学院的工商管理硕士学位和萨福克大学的学士学位。
Michael S. Wyzga has served on Mereo BioPharma Group plc Board since April 2019 following the closing of the merger between the Company and OncoMed Pharmaceuticals, Inc. (the "Merger"), and served as a director of OncoMed from October 2013 until the closing of the Merger. Mr. Wyzga is currently the President of MSW Consulting Inc., a strategic consulting group focused in the life sciences area. From December 2011 until November 2013, Mr. Wyzga served as President and Chief Executive Officer and a member of the board of directors of Radius Health, Inc. Prior to that, Mr. Wyzga served in various senior management positions at Genzyme Corporation, including as Chief Financial Officer from July 1999 until November 2011. Mr. Wyzga is currently Chairman of the board of directors of GenSight Biologics S.A. and Lead Independent Director of X4 Pharmaceuticals, Inc. Mr. Wyzga previously served as a member of the boards of directors of Adagio Therapeutics, LogicBio, Exact Sciences Corporation, Idenix Pharmaceuticals, Inc. and Altus Pharmaceuticals, Inc., and as a member of the supervisory board of Prosensa Holding B.V. He received an M.B.A. from Providence College and a B.S. from Suffolk University. - Michael S. Wyzga，自2019年3月合并完成后担任董事会成员。在合并之前，Wyzga先生自2018年7月起担任X4董事会主席。Wyzga先生目前是MSW Consulting Inc.的总裁。2011年12月至2013年11月，Wyzga先生在上市的生物制药公司Radius Health, Inc.担任总裁兼首席执行官和董事会成员。在此之前，Wyzga先生曾在全球生物技术上市公司健赞担任多个高级管理职位。Wyzga先生于1998年2月加入健赞，最近于2003年5月至2011年11月担任财务执行副总裁，并于1999年7月至2011年11月担任首席财务官。2014年2月至2018年12月，Wyzga先生担任上市生物制药公司Akebia Therapeutics, Inc.的董事会成员，同时也是薪酬委员会成员和审计委员会主席。自2015年2月起，Wyzga先生还担任医疗技术上市公司Exact Sciences Corporation的董事会成员。自2013年10月起至2019年4月Oncomed Pharmaceuticals, Inc.与Mereo BioPharma Group plc进行企业合并之前，Wyzga先生一直担任Oncomed Pharmaceuticals, Inc.的董事会成员，同时他还是审计委员会的成员。自2016年2月起，Wyzga先生还担任泛欧交易所上市生物制药公司GenSight Biologics S.A.的董事会主席。Wyzga先生此前还曾担任β胞核嘧啶制药的董事会成员，并于2014年6月起担任上市生物制药公司Prosensa Holding B.V。的监事会成员，直至2014年12月BioMarin Falcon B.V。收购Prosensa.他获得了普罗维登斯学院的工商管理硕士学位和萨福克大学的学士学位。
- Michael S. Wyzga has served on Mereo BioPharma Group plc Board since April 2019 following the closing of the merger between the Company and OncoMed Pharmaceuticals, Inc. (the "Merger"), and served as a director of OncoMed from October 2013 until the closing of the Merger. Mr. Wyzga is currently the President of MSW Consulting Inc., a strategic consulting group focused in the life sciences area. From December 2011 until November 2013, Mr. Wyzga served as President and Chief Executive Officer and a member of the board of directors of Radius Health, Inc. Prior to that, Mr. Wyzga served in various senior management positions at Genzyme Corporation, including as Chief Financial Officer from July 1999 until November 2011. Mr. Wyzga is currently Chairman of the board of directors of GenSight Biologics S.A. and Lead Independent Director of X4 Pharmaceuticals, Inc. Mr. Wyzga previously served as a member of the boards of directors of Adagio Therapeutics, LogicBio, Exact Sciences Corporation, Idenix Pharmaceuticals, Inc. and Altus Pharmaceuticals, Inc., and as a member of the supervisory board of Prosensa Holding B.V. He received an M.B.A. from Providence College and a B.S. from Suffolk University.
高管简历
中英对照 | 中文 | 英文- Denise Scots Knight
Denise Scots Knight，是Mereo BioPharma Group plc（一家专业生物制药公司）的共同创始人，也是其首席执行官和董事会成员，她自2015年以来一直担任该职位。Scots-Knight博士在生物制药行业拥有超过25年的经验，从事研发管理工作，并担任风险投资家。从2010年到2015年，Scots-Knight博士是全球生命科学风险投资公司Phase4 Partners Ltd.的管理合伙人。2004年至2010年，Scots-Knight博士担任野村Phase4 Ventures的负责人，该公司是日本领先金融机构野村国际集团（Nomura International plc）的风险投资附属公司。Scots-Knight博士曾在Oncomed Pharmaceuticals, Inc.、β胞核嘧啶制药、Nabriva Therapeutics AG和AlbireO的董事会任职。此外，Scots-Knight博士还被Labiotech UG评为欧洲生物技术领域15位领先的女性之一。
Denise Scots Knight is a co founder of Mereo and has served as Mereo BioPharma Group plc Chief Executive Officer since July 2015 and as a member of Mereo BioPharma Group plc Board of Directors since Mereo BioPharma Group plc formation. Prior to co founding Mereo, she served as Managing Partner at Phase4 Partners Ltd. ("Phase4"), a venture capital firm investing globally in biotechnology companies which was an MBO from Nomura, where Dr Scots Knight previously worked. Dr. Scots Knight is currently a board member of Elanco Animal Health Incorporated and previously served as a member of the board of directors of Idenix Pharmaceuticals (acquired by Merck) and Albireo Pharma (acquired by Ipsen), and also previously served as a Trustee at the British Heart Foundation for nine years. Dr. Scots Knight holds a Ph.D. in biochemistry from the University of Birmingham and was a Fulbright Scholar at the University of Berkeley, California.- Denise Scots Knight，是Mereo BioPharma Group plc（一家专业生物制药公司）的共同创始人，也是其首席执行官和董事会成员，她自2015年以来一直担任该职位。Scots-Knight博士在生物制药行业拥有超过25年的经验，从事研发管理工作，并担任风险投资家。从2010年到2015年，Scots-Knight博士是全球生命科学风险投资公司Phase4 Partners Ltd.的管理合伙人。2004年至2010年，Scots-Knight博士担任野村Phase4 Ventures的负责人，该公司是日本领先金融机构野村国际集团（Nomura International plc）的风险投资附属公司。Scots-Knight博士曾在Oncomed Pharmaceuticals, Inc.、β胞核嘧啶制药、Nabriva Therapeutics AG和AlbireO的董事会任职。此外，Scots-Knight博士还被Labiotech UG评为欧洲生物技术领域15位领先的女性之一。
- Denise Scots Knight is a co founder of Mereo and has served as Mereo BioPharma Group plc Chief Executive Officer since July 2015 and as a member of Mereo BioPharma Group plc Board of Directors since Mereo BioPharma Group plc formation. Prior to co founding Mereo, she served as Managing Partner at Phase4 Partners Ltd. ("Phase4"), a venture capital firm investing globally in biotechnology companies which was an MBO from Nomura, where Dr Scots Knight previously worked. Dr. Scots Knight is currently a board member of Elanco Animal Health Incorporated and previously served as a member of the board of directors of Idenix Pharmaceuticals (acquired by Merck) and Albireo Pharma (acquired by Ipsen), and also previously served as a Trustee at the British Heart Foundation for nine years. Dr. Scots Knight holds a Ph.D. in biochemistry from the University of Birmingham and was a Fulbright Scholar at the University of Berkeley, California.
- Charles Sermon
Charles Sermon自2015年7月起担任Mereo的总法律顾问兼公司秘书。从2010年到加入Mereo，他曾担任Phase4公司的合伙人，在那里他目前担任董事会成员。Sermon先生在完成律师协会（Law Society）的期末考试后，在Freshfields接受了律师培训并获得律师资格。Sermon先生拥有法学学士学位。荣誉。来自赫尔大学。
Charles Sermon is a co founder of Mereo and serves as Mereo BioPharma Group plc General Counsel and Business Development and has served as Mereo BioPharma Group plc General Counsel since July 2015. Prior to co founding Mereo, Mr Sermon was a partner at Phase4 and prior to that, he worked at Nomura. Mr. Sermon is currently a trustee of the Rainbow Trust Children's Charity. Mr. Sermon trained and qualified as a lawyer with Freshfields in London and holds an LLB (Hons) from the University of Hull, U.K.- Charles Sermon自2015年7月起担任Mereo的总法律顾问兼公司秘书。从2010年到加入Mereo，他曾担任Phase4公司的合伙人，在那里他目前担任董事会成员。Sermon先生在完成律师协会（Law Society）的期末考试后，在Freshfields接受了律师培训并获得律师资格。Sermon先生拥有法学学士学位。荣誉。来自赫尔大学。
- Charles Sermon is a co founder of Mereo and serves as Mereo BioPharma Group plc General Counsel and Business Development and has served as Mereo BioPharma Group plc General Counsel since July 2015. Prior to co founding Mereo, Mr Sermon was a partner at Phase4 and prior to that, he worked at Nomura. Mr. Sermon is currently a trustee of the Rainbow Trust Children's Charity. Mr. Sermon trained and qualified as a lawyer with Freshfields in London and holds an LLB (Hons) from the University of Hull, U.K.
- Alexandra Hughes Wilson
Alexandra Hughes Wilson自2018年3月起担任Mereo的患者准入和商业计划主管。在加入Mereo之前，Hughes-Wilson女士是瑞典孤儿BioVitrum Publ的高级副总裁，首席病人接入官。AB，一家生物技术公司，从2012年到2018年以及在此之前，在生物技术公司Genzyme（现称Sanofi Genzyme）担任Vice President健康和市场准入政策EMEA。Hughes-Wilson女士拥有法律和政治学士学位（荣誉）。（来自英国达勒姆大学。
Alexandra Hughes Wilson has served as Mereo BioPharma Group plc Chief Patient Access and Commercial Planning since March 2018. Prior to joining Mereo, Ms. Hughes Wilson served as Chief Patient Access Officer and Senior Vice President of Patient Access & External Affairs at Swedish Orphan Biovitrum (Sobi) from 2012 to 2018 and prior to that, she served as Vice President of Health & Market Access Policy EMEA at Genzyme Corporation (now Sanofi Genzyme). Ms. Hughes Wilson has been actively involved in rare disease policy, serving as Industry Coordinator on the European Commission's Committee of Experts on Rare Diseases and as Industry Lead on the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) Working Group with Interested Parties, and since 2024, has served as a Non Executive Director of Vaso Dynamics. Ms. Hughes Wilson holds an honors degree in Law and Politics from the University of Durham, U.K.- Alexandra Hughes Wilson自2018年3月起担任Mereo的患者准入和商业计划主管。在加入Mereo之前，Hughes-Wilson女士是瑞典孤儿BioVitrum Publ的高级副总裁，首席病人接入官。AB，一家生物技术公司，从2012年到2018年以及在此之前，在生物技术公司Genzyme（现称Sanofi Genzyme）担任Vice President健康和市场准入政策EMEA。Hughes-Wilson女士拥有法律和政治学士学位（荣誉）。（来自英国达勒姆大学。
- Alexandra Hughes Wilson has served as Mereo BioPharma Group plc Chief Patient Access and Commercial Planning since March 2018. Prior to joining Mereo, Ms. Hughes Wilson served as Chief Patient Access Officer and Senior Vice President of Patient Access & External Affairs at Swedish Orphan Biovitrum (Sobi) from 2012 to 2018 and prior to that, she served as Vice President of Health & Market Access Policy EMEA at Genzyme Corporation (now Sanofi Genzyme). Ms. Hughes Wilson has been actively involved in rare disease policy, serving as Industry Coordinator on the European Commission's Committee of Experts on Rare Diseases and as Industry Lead on the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) Working Group with Interested Parties, and since 2024, has served as a Non Executive Director of Vaso Dynamics. Ms. Hughes Wilson holds an honors degree in Law and Politics from the University of Durham, U.K.
- John Lewicki
John Lewicki自2020年7月起担任Mereo BioPharma Group PLC首席科学官。在加入Mereo之前，Lewicki博士曾在OncoMed Pharmaceuticals担任领导职务，此前曾担任研发高级副总裁，2018年3月至2019年4月担任总裁、首席执行官和董事会成员。此前，Lewicki博士曾担任Scios Inc的研究副总裁，他是该团队的一员，该团队共同发现了人类B型利钠肽，后来商业化用于治疗急性充血性心力衰竭。Lewicki博士在加州大学圣地亚哥分校获得博士学位。他与人合著了80多篇科学出版物，是30多项已获授权的美国专利的发明人。
John Lewicki has served as Mereo BioPharma Group plc Chief Scientific Officer since July 2020. Prior to joining Mereo, Dr. Lewicki held leadership roles at OncoMed Pharmaceuticals, serving as President, CEO, and a board member from March 2018 to April 2019, following earlier tenures as Senior Vice President of R&D. Previously, Dr. Lewicki served as Vice President of Research at Scios Inc, where he was part of the team that co discovered human B type natriuretic peptide, later commercialized as a treatment for acute congestive heart failure. Dr. Lewicki earned his Ph.D. from the University of California, San Diego. He has co authored over 80 scientific publications and is an inventor on more than 30 issued U.S. patents.- John Lewicki自2020年7月起担任Mereo BioPharma Group PLC首席科学官。在加入Mereo之前，Lewicki博士曾在OncoMed Pharmaceuticals担任领导职务，此前曾担任研发高级副总裁，2018年3月至2019年4月担任总裁、首席执行官和董事会成员。此前，Lewicki博士曾担任Scios Inc的研究副总裁，他是该团队的一员，该团队共同发现了人类B型利钠肽，后来商业化用于治疗急性充血性心力衰竭。Lewicki博士在加州大学圣地亚哥分校获得博士学位。他与人合著了80多篇科学出版物，是30多项已获授权的美国专利的发明人。
- John Lewicki has served as Mereo BioPharma Group plc Chief Scientific Officer since July 2020. Prior to joining Mereo, Dr. Lewicki held leadership roles at OncoMed Pharmaceuticals, serving as President, CEO, and a board member from March 2018 to April 2019, following earlier tenures as Senior Vice President of R&D. Previously, Dr. Lewicki served as Vice President of Research at Scios Inc, where he was part of the team that co discovered human B type natriuretic peptide, later commercialized as a treatment for acute congestive heart failure. Dr. Lewicki earned his Ph.D. from the University of California, San Diego. He has co authored over 80 scientific publications and is an inventor on more than 30 issued U.S. patents.
- Christine Fox
Christine Fox自2021年1月起担任Mereo BioPharma Group PLC 首席财务官。在加入Mereo之前，Fox女士是Travelport Worldwide有限公司的集团财务总监和财务主管，在此之前，她曾在美国和瑞士的毕马威会计师事务所服务过十多年。Fox女士是一名注册会计师（CPA），拥有巴特勒大学会计学学士学位。
Christine Fox has served as Mereo BioPharma Group plc Chief Financial Officer since January 2021. Before joining Mereo, Ms. Fox was the Group Financial Controller and Treasurer at Travelport Worldwide Ltd. and prior to that, she served over a decade at KPMG in the U.S. and Switzerland. Ms. Fox is a Certified Public Accountant (CPA) and holds a Bachelor of Science in Accounting from Butler University.- Christine Fox自2021年1月起担任Mereo BioPharma Group PLC 首席财务官。在加入Mereo之前，Fox女士是Travelport Worldwide有限公司的集团财务总监和财务主管，在此之前，她曾在美国和瑞士的毕马威会计师事务所服务过十多年。Fox女士是一名注册会计师（CPA），拥有巴特勒大学会计学学士学位。
- Christine Fox has served as Mereo BioPharma Group plc Chief Financial Officer since January 2021. Before joining Mereo, Ms. Fox was the Group Financial Controller and Treasurer at Travelport Worldwide Ltd. and prior to that, she served over a decade at KPMG in the U.S. and Switzerland. Ms. Fox is a Certified Public Accountant (CPA) and holds a Bachelor of Science in Accounting from Butler University.